

Jooryung Huh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3424255/publications.pdf>

Version: 2024-02-01

136
papers

2,337
citations

218677

26
h-index

276875

41
g-index

139
all docs

139
docs citations

139
times ranked

3964
citing authors

#	ARTICLE	IF	CITATIONS
1	Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification. <i>American Journal of Hematology</i> , 2010, 85, 760-764.	4.1	109
2	Epidemiologic overview of malignant lymphoma. <i>The Korean Journal of Hematology</i> , 2012, 47, 92.	0.7	95
3	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	1.8	93
4	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	1.8	72
5	WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study. <i>Korean Journal of Pathology</i> , 2011, 45, 254.	1.3	68
6	Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 352-358.	1.1	67
7	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	64
8	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	1.8	61
9	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.0	60
10	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	59
11	Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 1999, 60, 205-214.	4.1	48
12	Clinical features, tumor biology, and prognosis associated with <i>MYC</i> rearrangement and <i>Myc</i> overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	5.5	48
13	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	7.0	48
14	CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , 2014, 9, e87066.	2.5	46
15	Cutaneous extranodal natural killer/T-cell lymphoma: A comparative clinicopathologic and survival outcome analysis of 45 cases according to the primary tumor site. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1002-1009.	1.2	44
16	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. <i>Tumor Biology</i> , 2016, 37, 7507-7514.	1.8	40
17	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.5	39
18	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1883-1890.	1.8	37

#	ARTICLE	IF	CITATIONS
19	Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas. Korean Journal of Pathology, 2014, 48, 81.	1.3	36
20	¹⁸ F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in ¹⁸ F-FDG avidity according to site involvement. Leukemia and Lymphoma, 2015, 56, 3288-3294.	1.3	36
21	Prognostic impact of c-Rel nuclear expression and c-REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	1.8	35
22	MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma. Histopathology, 2016, 68, 442-449.	2.9	34
23	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget, 2016, 7, 76934-76943.	1.8	33
24	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
25	RelA NF- κ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	3.1	29
26	Endoscopic features and clinical outcomes of colorectal mucosa-associated lymphoid tissue lymphoma. Gastrointestinal Endoscopy, 2018, 87, 529-539.	1.0	28
27	Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma. Korean Journal of Pathology, 2013, 47, 526.	1.3	27
28	Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. PLoS ONE, 2016, 11, e0167641.	2.5	27
29	RGS1 expression is associated with poor prognosis in multiple myeloma. Journal of Clinical Pathology, 2017, 70, 202-207.	2.0	27
30	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. Journal of Hematology and Oncology, 2020, 13, 148.	17.0	27
31	Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems. Journal of Korean Medical Science, 2014, 29, 53.	2.5	26
32	Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. Blood Research, 2014, 49, 253.	1.3	26
33	Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Advances, 2021, 5, 3919-3930.	5.2	26
34	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. Cancer Research and Treatment, 2020, 52, 374-387.	3.0	26
35	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma. Hematological Oncology, 2016, 34, 22-27.	1.7	25
36	Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. Blood Advances, 2021, 5, 2142-2152.	5.2	23

#	ARTICLE	IF	CITATIONS
37	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
38	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
39	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	5.5	21
40	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	3.4	20
41	GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. Journal of Pathology and Translational Medicine, 2017, 51, 152-158.	1.1	20
42	Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Research, 2017, 52, 285.	1.3	19
43	Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. International Journal of Hematology, 2019, 110, 86-94.	1.6	19
44	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	3.1	19
45	Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. Annals of Hematology, 2016, 95, 801-808.	1.8	18
46	Cutaneous anaplastic large-cell lymphoma (ALCL): A comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site. Journal of the American Academy of Dermatology, 2016, 74, 1135-1143.	1.2	18
47	Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma. Hematological Oncology, 2018, 36, 182-188.	1.7	18
48	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	5.5	17
49	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer, 2019, 19, 1080.	2.6	17
50	The clinical outcomes of rituximab biosimilar CT-P10 (Truxima [®]) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leukemia and Lymphoma, 2020, 61, 1575-1583.	1.3	17
51	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. Blood Research, 2013, 48, 266.	1.3	16
52	LGALS3 as a prognostic factor for classical Hodgkin's lymphoma. Modern Pathology, 2014, 27, 1338-1344.	5.5	16
53	The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age. Hematological Oncology, 2015, 33, 133-140.	1.7	16
54	Diagnostic utility of STAT6/EB3 expression in classical Hodgkin lymphoma and related entities. Modern Pathology, 2020, 33, 834-845.	5.5	16

#	ARTICLE	IF	CITATIONS
55	Congenital CD34-positive granular cell dendrocytosis. <i>Journal of Cutaneous Pathology</i> , 1999, 26, 253-258.	1.3	15
56	Interim 18F-FDG PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine. <i>Annals of Hematology</i> , 2017, 96, 1509-1515.	1.8	15
57	EBV-associated T and NK cell lymphoproliferative disorders: consensus report of the 4th Asian Hematopathology Workshop. <i>Journal of Hematopathology</i> , 2012, 5, 319-324.	0.4	14
58	Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. <i>Blood Research</i> , 2014, 49, 170.	1.3	14
59	A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1249-1258.	1.8	13
60	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	1.8	13
61	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. <i>Oncotarget</i> , 2017, 8, 58122-58132.	1.8	13
62	TdT+ T-Lymphoblastic Proliferation in Castleman Disease. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 1-4.	1.1	13
63	Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 224-241.	1.1	12
64	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 2630-2636.	1.3	11
65	18F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 249-256.	1.0	10
66	Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1657-1664.	1.8	10
67	Diagnostic Pitfalls of Merkel Cell Carcinoma and Dramatic Response to Chemotherapy. <i>Journal of Dermatology</i> , 1998, 25, 322-328.	1.2	9
68	Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. <i>Korean Journal of Pathology</i> , 2014, 48, 209.	1.3	9
69	Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study. <i>Journal of Hematopathology</i> , 2019, 12, 173-181.	0.4	9
70	Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 66-74.	1.3	9
71	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β_2 -microglobulin Levels. <i>Cancer Research and Treatment</i> , 2021, 53, 847-856.	3.0	9
72	<sc>TCL</sc>1 expression predicts overall survival in patients with mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 583-594.	2.2	8

#	ARTICLE	IF	CITATIONS
73	Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 594692.	2.8	8
74	Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 329.	2.8	8
75	An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 753-757.	1.7	8
76	Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients. <i>Blood Research</i> , 2017, 52, 125.	1.3	7
77	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	6.2	7
78	Tumor implantation along abdominal trocar site after laparoscopic removal of malignant ovarian tumor: a case report. <i>Journal of Korean Medical Science</i> , 1996, 11, 440.	2.5	6
79	Relationship between Endometrial Estrogen and Progesterone Receptors, and Sonographic Endometrial Appearance in the Preovulatory Phase. <i>Journal of Obstetrics and Gynaecology Research</i> , 2000, 26, 95-101.	1.3	6
80	A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity. <i>Korean Journal of Pathology</i> , 2014, 48, 426-429.	1.3	6
81	Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma. <i>Blood Research</i> , 2017, 52, 270.	1.3	6
82	Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). <i>Hematological Oncology</i> , 2018, 36, 56-61.	1.7	6
83	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). <i>Oncotarget</i> , 2017, 8, 13367-13374.	1.8	6
84	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. <i>Modern Pathology</i> , 2022, 35, 480-488.	5.5	6
85	Recurrence patterns of mucosa-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience. <i>Hematology</i> , 2016, 21, 542-548.	1.5	5
86	Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma. <i>Blood Research</i> , 2019, 54, 285-288.	1.3	5
87	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2020, 61, 1119-1125.	1.3	5
88	Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2. <i>Scientific Reports</i> , 2020, 10, 10680.	3.3	5
89	Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 2880.	3.3	5
90	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 330-337.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Multistaining Optimization for Epstein-Barr Virus-Encoded RNA In Situ Hybridization and Immunohistochemistry of Formalin-Fixed Paraffin-Embedded Tissues Using an Automated Immunostainer. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 317-326.	1.1	5
92	Reed-Sternberg-like cells in follicular lymphoma. <i>Blood Research</i> , 2014, 49, 147.	1.3	4
93	Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. <i>International Journal of Experimental Pathology</i> , 2015, 96, 232-239.	1.3	4
94	Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis. <i>Blood Research</i> , 2017, 52, 221.	1.3	4
95	A prognostic index for extranodal marginal zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β_2 -microglobulin levels. <i>British Journal of Haematology</i> , 2021, 193, 307-315.	2.5	4
96	The limited role of comprehensive staging workup in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis. <i>British Journal of Haematology</i> , 2021, 193, 848-851.	2.5	4
97	Prognostic significance of serum β_2 -microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2021, , 1-7.	1.3	4
98	Primary mediastinal large B-cell lymphoma: a single-center experience in Korea. <i>Blood Research</i> , 2014, 49, 36.	1.3	3
99	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. <i>Blood Research</i> , 2014, 49, 115.	1.3	3
100	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). <i>Annals of Hematology</i> , 2020, 99, 2831-2836.	1.8	3
101	Primary Follicular Lymphoma of the Duodenum: A Case Report. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 479-481.	1.1	3
102	Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient. <i>Cancer Research and Treatment</i> , 2015, 47, 539-543.	3.0	3
103	A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum β_2 -Microglobulin to PINK. <i>Cancer Research and Treatment</i> , 2023, 55, 314-324.	3.0	3
104	The First Korean Case of Epstein-Barr Virus-positive Natural Killer/T-cell Lymphoma That Progressed From Severe Mosquito Bite Allergy, With Coexistence of Hemophagocytic Lymphohistiocytosis. <i>Annals of Laboratory Medicine</i> , 2020, 40, 80-83.	2.5	2
105	Clinicopathological and prognostic significance of BCL2, BCL6, MYC, and IRF4 copy number gains and translocations in follicular lymphoma: a study by FISH analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 3342-3350.	1.3	2
106	Burkitt's Lymphoma in Korea: Clinical Manifestations and Efficacy of Modified CALGB 9251 Regimen (BNHL). <i>Blood</i> , 2005, 106, 4661-4661.	1.4	2
107	A Phase I Trial of Bortezomib Plus CHOP Every 2 Weeks in Patients with Advanced Stage Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2007, 110, 4446-4446.	1.4	2
108	The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study. <i>Blood</i> , 2010, 116, 1791-1791.	1.4	2

#	ARTICLE	IF	CITATIONS
109	VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center. <i>The Korean Journal of Hematology</i> , 2008, 43, 138.	0.7	2
110	Splenic rupture in primary amyloidosis with chronic neutrophilic leukemia. <i>Blood Research</i> , 2015, 50, 5.	1.3	1
111	Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study. <i>Cancer Research and Treatment</i> , 2021, 53, 270-278.	3.0	1
112	Central Nervous System Relapse in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 5346-5346.	1.4	1
113	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide Conditioning in Patients with Primary Central Nervous System Lymphoma: A Remarkable Outcome Form Single-Center Experience. <i>Blood</i> , 2016, 128, 3462-3462.	1.4	1
114	PROGNOSTIC SIGNIFICANCE of CD68 EXPRESSION for Korean PATIENTS with HODGKIN'S LYMPHOMA. <i>Blood</i> , 2010, 116, 3888-3888.	1.4	1
115	Prognostic Value of Positron Emission Tomography- Computed Tomography in Patients with Marginal Zone Lymphoma. <i>Blood</i> , 2012, 120, 5084-5084.	1.4	1
116	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 365-365.	1.4	1
117	Ureteral Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Chronic Inflammation, and Renal Artery Atherosclerosis. <i>Journal of Pathology and Translational Medicine</i> , 2015, 49, 339-342.	1.1	1
118	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. <i>Blood</i> , 2021, 138, 2395-2395.	1.4	1
119	Relationship between endometrial estrogen and progesterone receptors, and sonographic endometrial appearance in the preovulatory phase. <i>Journal of Obstetrics and Gynaecology Research</i> , 2002, 28, 233-235.	1.3	0
120	Blastic plasmacytoid dendritic cell neoplasm in the CSF. <i>Blood Research</i> , 2017, 52, 158.	1.3	0
121	Follicular lymphoma with prominent Dutcher body formation after liver transplantation. <i>Blood Research</i> , 2019, 54, 84-84.	1.3	0
122	JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. <i>Annals of Laboratory Medicine</i> , 2020, 40, 1-6.	2.5	0
123	BEAC or BEAM Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients: Comparative Analysis on Efficacy and Toxicity.. <i>Blood</i> , 2005, 106, 5291-5291.	1.4	0
124	Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults; Retrospective Analysis of 36 Patients.. <i>Blood</i> , 2006, 108, 4633-4633.	1.4	0
125	Immunohistochemical Prognostic Marker for Diffuse Large B Cell Lymphoma in Patients Treated with CHOP Like Chemotherapy: Validation of the Algorithm by Hans Et Al. and Analysis of Individual Markers. <i>Blood</i> , 2008, 112, 5274-5274.	1.4	0
126	Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?. <i>Blood</i> , 2008, 112, 2833-2833.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Primary Mediastinal Large B-Cell Lymphoma: A Single Center Experience in Korea.. Blood, 2009, 114, 5013-5013.	1.4	0
128	SIGNIFICANCE of ABSOLUTE LYMPHOCYTE COUNT at RELAPSE as a PROGNOSTIC FACTOR in PATIENTS with T-CELL NON-HODGKIN'S LYMPHOMA.. Blood, 2009, 114, 2939-2939.	1.4	0
129	Associations of Methylene Tetrahydrofolate Reductase Polymorphism and Methotrexate-Related Toxicities in Korean Treated for Malignant Lymphoma. Blood, 2011, 118, 1607-1607.	1.4	0
130	Clinical Significance of Immunoglobulin Isotype Switching in Patients with Multiple Myeloma. Blood, 2012, 120, 4980-4980.	1.4	0
131	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	1.4	0
132	Prognostic Impact Of Beta-2 Microglobulin In Patients With Non-Gastric Marginal Zone Lymphoma. Blood, 2013, 122, 4297-4297.	1.4	0
133	Immunohistochemical Study for Expression of p53, bcl-2 and Bax in Uterine Sarcoma. Korean Journal of Gynecologic Oncology and Colposcopy, 1997, 8, 395.	0.0	0
134	The Brenner Tumors of The Ovary: A Clinicopathologic Study. Korean Journal of Gynecologic Oncology and Colposcopy, 1998, 9, 168.	0.0	0
135	Prognostic Value of Serum Beta-2 Microglobulin during and after Completing Chemotherapy in Marginal Zone Lymphoma. Blood, 2018, 132, 5335-5335.	1.4	0
136	Central Nervous System Relapse in Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2018, 132, 1634-1634.	1.4	0